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Abstract
Background
Atrial fibrillation (AF) is a major contributor to the global cardiovascular disease burden. The
clinical profile and outcomes of AF patients with valvular heart diseases in sub-Saharan
Africa (SSA) have not been adequately described. We assessed clinical features and 12-
month outcomes of patients with valvular AF (vAF) in comparison to AF patients without val-
vular heart disease (nvAF) in western Kenya.
Methods
We performed a cohort study with retrospective data gathering to characterize risk factors
and prospective data collection to characterize their hospitalization, stroke and mortality
rates.
Results
The AF patients included 77 with vAF and 69 with nvAF. The mean (SD) age of vAF and
nvAF patients were 37.9(14.5) and 69.4(12.3) years, respectively. There were significant dif-
ferences (p<0.001) between vAF and nvAF patients with respect to female sex (78% vs.
55%), rates of hypertension (29% vs. 73%) and heart failure (10% vs. 49%). vAF patients
were more likely to be taking anticoagulation therapy compared to those with nvAF (97% vs.
76%; p<0.01). After 12-months of follow-up, the overall mortality, hospitalization and stroke
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rates for vAF patients were high, at 10%, 34% and 5% respectively, and were similar to the
rates in the nvAF patients (15%, 36%, and 5%, respectively).
Conclusion
Despite younger age and few comorbid conditions, patients with vAF in this developing
country setting are at high risk for nonfatal and fatal outcomes, and are in need of interven-
tions to improve short and long-term outcomes.
Introduction
Atrial fibrillation (AF) is the most common cardiac arrhythmia affecting over 33 million peo-
ple worldwide [1,2]. AF is associated with increased risk of stroke, heart failure and mortality
[3–5]. Variations in AF incidence and complications have been observed by age, gender and
race [5]. Although previous studies in high-income countries have reported a lower prevalence
of AF in people of African descent compared to those of European ancestry [6], AF is becom-
ing increasingly common in sub-Saharan Africa [7]. Between 1990 and 2010, AF represented
the largest relative increase in cardiovascular disease burden in sub-Saharan Africa (SSA)
going from 0.7% to 1% [7], while rates of other cardiovascular diseases such as ischemic heart
diseases increased at a much lower rate over the same period. Nonetheless, there remains a
paucity of data on clinical characteristics and outcomes associated with AF in this region.
Although rheumatic heart disease (RHD) is relatively rare in high-income countries, it
remains a major risk factor of AF in low-income countries where it is present in nearly one
out of five patients with AF [8]. Patients with RHD tend to be younger and more often women
of reproductive age [9]. It is estimated that 8% of strokes in low and middle-income countries
could be due to complications of RHD [10]. Despite the magnitude of the problem, these
patients are usually excluded from research studies related to AF, particularly larger clinical tri-
als of anticoagulation therapy. As a result, there is sparse data assessing characteristic and out-
comes of patients with valvular diseases and AF. And, it is still unknown if AF patients with or
without valvular diseases have a similar risk of stroke, mortality or hospitalization. Given the
rapid increase in the prevalence of AF in SSA, it is imperative to understand the clinical char-
acteristics and outcomes of AF patients, in particular the differences between valvular and
non-valvular AF populations. In this study, we evaluated clinical characteristics, treatment pat-
terns and 12-month outcomes of valvular AF patients in comparison to the non-valvular AF
patients enrolled in the Study of Genetics of Atrial Fibrillation in an African Population (SIG-
NAL) study.
Methods
Study population and design
As previously described in detail [11], SIGNAL is a study designed to determine characteris-
tics, treatment patterns, 12-month outcomes and genetic associations in patients with AF in
western Kenya. The study consisted of retrospective data-gathering during study enrollment
to characterize the differences between valvular and non-valvular AF patients, and prospective
data collection 12-month after enrollment to characterize their hospitalization, stroke and
mortality rates. We enrolled adult patients (>18 years) with a diagnosis of AF who presented
to the cardiology clinic, inpatient wards, medical outpatient clinic, anticoagulation clinic or
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the cardiac noninvasive diagnostic unit at Moi Teaching and Referral Hospital (MTRH) in
Eldoret, Kenya. Patients were enrolled consecutively. This site was chosen because of its broad
mix of patients including a mix of urban middle class, urban poor and rural populations and
presence of an NHLBI-supported Cardiovascular Center of Excellence in research at MTRH
[12]. The study sample included two groups of AF patients, those with valvular AF (vAF) and
those with non-valvular AF (nvAF). Both prevalent and incident cases of AF were included,
and no distinction was made according to duration of AF episodes. Atrial Fibrillation had to
be recorded on at least one 12-lead electrocardiogram (ECG). Patients with known genetic
syndromes, congenital heart defects, and other severe illnesses precluding ECG or echocardio-
gram were excluded. Detailed inclusion and exclusion criteria have been published previously
[11].
Study procedure
The Institutional Research and Ethics Committee of Moi University School of Medicine, and
the Institutional Review Boards of Indiana University and Duke University approved the
study. All patients provided written informed consent. Medical history, physical examination,
biochemical analysis, 12-lead electrocardiogram and an echocardiogram were performed at
baseline. The diagnosis of nvAF was based on ruling out significant valvular heart disease
through a combination of history, echocardiogram, ECG, and clinical findings. Data were col-
lected using a standardized case report form. We calculated each participant’s CHADS2 score
to assess stroke risk in which one point is assigned for each of the following characteristics: a
history of congestive heart failure, hypertension, age75 years, or diabetes mellitus, and 2
points are assigned for a history of stroke or transient ischemic attack [13]. Sufficient data
were not available to calculate a CHA2DS2-VASc score. The 12-month follow-up was carried
out by telephone or in-person interview.
Outcomes
The main study outcomes were all-cause mortality, stroke and cardiac hospitalization. Com-
bined adverse events (CAE) was defined as a composite of all-cause mortality, stroke and car-
diac hospitalization. Death and hospitalization were determined as reported by the participant
or the relatives of the participant during follow-up by telephone and, when possible, medical
records were also reviewed. Deaths were further classified as being cardiovascular (e.g. sudden
cardiac death, heart failure, stroke and other vascular causes) or non-cardiovascular due to
other specified causes (e.g. malignancy, infection etc.). Stroke was also determined as reported
by the relatives or patients and, when possible, medical records were also reviewed. Mortality
was treated as a time-to-event outcome while other outcomes were treated as binary.
Statistical analysis
Baseline clinical characteristics including demographics, medical history, and medical thera-
pies were compared between vAF and nvAF patients. Descriptive statistics for continuous vari-
ables were expressed as means (standard deviation [SD]) or median (interquartile range
[IQR]) while those for categorical variables were expressed as frequencies and percentages
unless otherwise specified. Comparisons of baseline characteristics and outcomes between
vAF and nvAF patients were conducted using Fisher’s exact test for categorical variables and
with t-tests or Wilcoxon rank-sum tests for continuous variables. Survival curves (all-cause
mortality) were created for the two groups of AF patients analyzed using the Kaplan–Meier
method, and compared using the log-rank test. A p< 0.05 was considered to be statistically
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significant. Statistical analysis was performed using SAS version 9.4. See supporting informa-
tion for the minimum dataset underlying our results.
Results
Baseline characteristics of SIGNAL patients
From October 2013 through July 2014, a total of 160 consecutive AF patients were screened.
Of these, 150 AF patients were enrolled in the study. The median duration of the follow-up
period was 12 (12–14) months. Follow up data was available for 77 vAF and 69 nvAF patients
with 4 patients lost to follow-up, yielding 146 AF patients (97%) included in the analysis (Fig
1). The baseline characteristics of the two groups are shown in Table 1. All patients with vAF
reported a history of rheumatic fever. Non-mutually exclusive, valvular heart diseases subtypes
included mitral regurgitation (86%), moderate to severe mitral stenosis (53%) and aortic
regurgitation (49%). vAF compared to nvAF patients were significantly younger and more
often females. They were less likely to have hypertension, heart failure, previous myocardial
infraction, history of alcohol consumption and tobacco use and had significantly lower systolic
Fig 1. Flow diagram of enrollment and12-months follow-up. Legend. AF = atrial fibrillation, LTFU = lost to follow up.
https://doi.org/10.1371/journal.pone.0185204.g001
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Table 1. Baseline characteristics of atrial fibrillation patients.
vAF
(n = 77)
nvAF
(n = 69)
p value
(vAF vs. nvAF)
Demographics
Female 60 (77.9) 38 (55.1) 0.005
Age, yrs 37.9 ± 14.5 69.4 ± 12.3 <0.001
Age groups <0.001
18–40 48 (62.3) 2 (2.9)
41–59 22 (28.6) 15 (21.7)
60–74 7 (9.1) 26 (37.7)
75 0 (0.0) 26 (37.7)
Medical history
Heart failure 6 (9.5) 33 (48.5) <0.001
Hypertension 22 (28.6) 50 (72.5) <0.001
Stroke 18 (23.4) 18 (26.1) 0.85
DM 1 (1.3) 6 (8.7) 0.052
RHD 77 (100) 0 (0.0) <0.001
Thyroid Disease 2 (3.0) 3 (5.0) 0.67
MI 4 (5.4) 8 (11.8) 0.23
Dsylipidemia 7 (9.2) 14 (20.3) 0.06
COPD 2 (2.7) 10 (14.9) 0.01
Heart surgery 16 (20.8) 0 (0.0) <0.001
HIV 2 (2.6) 4 (5.9) 0.42
Sleep apnea 4 (5.3) 5 (7.4) 0.74
Tobacco use 6 (7.8) 26 (37.7) <0.001
Alcohol drinking 12 (15.6) 40 (58.0) <0.001
Other characteristics
AF duration, yrs 6.6 ± 7.5 3.4 ± 6.6 0.007
SBP, mm Hg 114.9 ± 17.8 126.4 ± 23.0 0.001
DBP, mm Hg 73.1 ± 12.8 75.9 ± 16.2 0.25
Heart rate, beats/min 84.5 ± 21.1 80.6 ± 22.8 0.29
CHADS2 score Na 2.2 ± 1.3
BMI, kg/m2 22.0 ± 11.0 23.7 ± 5.1 0.23
NYHA Class 0.19
I 56 (73.7) 45 (65.2)
II 10 (13.2) 11 (15.9)
III 7 (9.2) 4 (5.8)
IV 3 (3.9) 9 (13.0)
Lab values
BNP, pg/mL (IQR) 745.2 (37.3–2543) 1288.5 (29.2–3895.0) 0.20
HbA1c, % 5.8 ± 0.6 6.0 ± 0.7 0.01
Creatinine, mmol/L 68.0 ± 18.7 76.0 ± 33.9 0.08
INR 2.4 ± 0.9 2.4 ± 0.9 0.81
hs-CRP, mmol/L 5.4 ± 7.4 8.8 ± 15.7 0.10
Echocardiographic characteristics
LV mass, g 158.3 ± 68.5 148.2 ± 57.3 0.38
LVEF, % 45.5 ± 10.7 43.5 ± 12.9 0.47
(Continued )
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blood pressure. Those with vAF had significantly larger left atrial volume than the nvAF
patients. Other lab data including creatinine were comparable between the two groups.
Treatment characteristics
The most frequent medications used in among AF patients were diuretics (76.7%), beta-block-
ers (49.3%) and digoxin (35.6%). Prescription of ACE inhibitors, beta-blockers and diuretics
were similar between the two groups (Table 2). Information on amiodarone and calcium
blockers drug treatment and history of electrical cardioversion, while available in our setting,
were not recorded. Treatments to achieve and maintain sinus rhythm such as catheter ablation
therapy are not available in our setting. None of the participants received direct oral anticoagu-
lant therapy, as these medications are not generally available to patients in this setting. 16 vAF
patients had undergone surgery for valve replacement or repair, valve replacement (12) or
repair (4). Nine patients had mitral valve replacement alone, one had aortic valve replacement
and one had combined aortic and mitral valve replacement. All replaced valves were mechani-
cal, and all repairs were mitral valve repairs. Significantly more vAF patients than nvAF receiv-
ed anticoagulation therapy (97.4% vs. 91.3%, p< 0.01). However, most of nvAF patients with
CHADS2 scores2 received warfarin (79.1%). All vAF participants who underwent valve
replacement or therapy were on warfarin. INR measurements were obtained for all AF patients
on warfarin therapy at enrollment and the overall mean was 2.4 (0.9). Of the vAF and nvAF
patients, 29.3% vs. 28.8% were in the sub-therapeutic range (<2.0), 52.0% vs. 55.9% in the
therapeutic range (2.0–3.0) and 18.7% vs. 15.2% above the therapeutic range (>3.0), respec-
tively. None of the participants received direct oral anticoagulant therapy, as these medications
are not generally available to patients in this setting.
Table 1. (Continued)
vAF
(n = 77)
nvAF
(n = 69)
p value
(vAF vs. nvAF)
LA volume, cm3 247.2 ± 142.4 111.4 ± 49.4 <0.001
Values are in n (%), median (interquartile range) or mean ± SD.
AF, Atrial fibrillation; nvAF, Non-valvular AF; vAF, Valvular AF; RHD, Rheumatic heart disease; COPD, chronic obstructive pulmonary disease; SBP,
Systolic BP; DBP, Diastolic BP; DM, Diabetes mellitus; MI, Myocardial infraction; hs-CRP, High-sensitivity C-reactive Protein; BNP, B-type Natriuretic
Peptide; LVEF, Left ventricular ejection fraction; LA, left atrial; LV, Left ventricular; na, not applicable.
https://doi.org/10.1371/journal.pone.0185204.t001
Table 2. Medication use before study entry for atrial fibrillation patients.
vAF
(n = 77)
nvAF
(n = 69)
p value
(vAF vs. nvAF)
Warfarin 75 (97.4) 56 (81.2) 0.002
Aspirin 0 (0.0) 7 (10.1) 0.004
Digoxin 32 (41.6) 20 (29.0) 0.12
ACE inhibitor 21 (27.3) 24 (34.8) 0.37
ARB 3 (3.9) 18 (26.1) <0.001
Diuretic 56 (72.7) 56 (81.2) 0.25
Beta-blocker 42 (54.5) 30 (43.5) 0.19
Values are n (%), ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptors blockers.
Other abbreviations as in Table 1
https://doi.org/10.1371/journal.pone.0185204.t002
Clinical outcomes of atrial fibrillation patients in Kenya
PLOS ONE | https://doi.org/10.1371/journal.pone.0185204 September 21, 2017 6 / 11
Mortality and cardiovascular outcomes
Table 3 shows 12-month event rates for each group where death is treated as a binary outcome.
Overall incidence of mortality, stroke, and cardiac related hospital admissions were high in
both groups without statistically significant differences. There were a total of 18 deaths (14 car-
diovascular, 1 non-cardiovascular, 3 with unknown cause of death), 7 strokes and 47 hospitali-
zations (39 for cardiac reasons) during the follow-up period. There were (8 vs. 10; p = 0.46)
deaths, (4 vs. 3; p = 1.00) stroke and (19 vs.20; p = 0.71) cardiac related hospitalization for vAF
and nvAF patients, respectively. There were no reported deaths among vAF who underwent
valve repair or replacement. Fig 2 presents the Kaplan-Meier survival curve (i.e., time-to-event
analysis) for the two AF patient groups.
Discussion
We demonstrated that vAF patients, who make up a large proportion of AF patients in SSA,
are a cohort of relatively young patients, predominantly women, less likely to have the tradi-
tional clinical characteristics related to poor outcomes including heart failure, hypertension,
diabetes and previous myocardial infraction, compared to their nvAF counterparts. Despite
differences in clinical profile and significantly younger age, the risk of death, stroke occurrence
and hospitalizations were similar to those of nvAF patients. This subgroup of AF patients with
valvular heart diseases attributed to rheumatic heart diseases (RHD) represents a group with
high morbidity and mortality, in need of interventions to improve outcomes.
The average age of vAF patients in this study was 38 years, significantly younger compared
to our nvAF cohort as well as the AF patients with RHD who participated in the RE-LY cohort
study [52 years) [8]. In addition to being younger, they were predominantly women, with a
large majority of childbearing age. Prior literature concurs that most RHD patients are women
[9]. Given the potential complications associated with maternal cardiovascular diseases and
the unique challenges for stroke prevention in pregnancy, the ability to both counsel patients
prior to pregnancy and appropriately manage these patients is of vital importance. Unfortu-
nately, the majority of the women with RHD in low-income countries are not aware of the
pre-existing heart disease until pregnancy. In this study, one fifth of women with vAF reported
Table 3. Comparison of outcomes of atrial fibrillation patients.
Outcomes vAF
(n = 77)
nVAF
(n = 69)
p-value
(vAF vs. nvAF)
All-cause mortality 8 (10.4) 10 (14.5) 0.46
Cause of death 0.40
Cardiovascular death 5 (62.5) 9 (90.0)
Non-Cardiovascular death 1 (12.5) 0 (0.0)
Unknown cause 2 (25.0) 1 (10.0)
Stroke † 4 (5.4) 3 (4.5) 1.00
Hospitalization 23 (31.1) 24 (35.8) 0.59
Cardiac-hospitalization ‡ 19 (25.7) 20 (29.9) 0.71
Combined adverse events 24 (31.2) 21 (30.4) 1.00
Values are n (%). Combined adverse events (composite of all-cause of mortality, stroke and cardiac hospitalization).
Other abbreviations as in Table 1.
†N = 140
‡N = 141
https://doi.org/10.1371/journal.pone.0185204.t003
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a previous stroke. Our results highlight the need for community based screening and preven-
tion of RHD in low-middle income countries.
The prevalence of cardiovascular disease risk factors, comorbid conditions, tobacco and
alcohol use were all significantly higher in nvAF patients than in vAF patients. Consistent with
previous reports, hypertension was the most common AF risk factor among the nvAF patients
(72%) but was less common in patients with vAF (28%) [5,14–17]. Diabetes prevalence was
strikingly low in both groups consistent with previous findings in patients with AF from SSA
[8]. With the expected aging of the population in SSA, we expect to see a surge in cardiovascu-
lar risk factors, particularly hypertension, which portends more risk for fatal outcomes. Thus,
in addition to rate control and anticoagulation therapy, there is a great need for comprehensive
strategies for prevention, treatment and control of hypertension in both groups of AF patients.
History of stroke in our AF cohorts was common and greater than seen in previous reports
from other countries in SSA [14–17]. Anticoagulation is recommended for all patients with
AF and RHD [18]. Oral anticoagulation therapy use was higher than reported in several world-
wide registries (4%-79%) [19–21]. However stroke occurred in 5.4% of the vAF cases during
Fig 2. Kaplan-meier survival curve for atrial fibrillation patients. Legend. AF = atrial fibrillation.
https://doi.org/10.1371/journal.pone.0185204.g002
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12 months’ follow-up, despite high use of warfarin, younger age and few cardiovascular risk
factors. The stroke rate for vAF patients is similar to that reported in the RE-LY global registry
of AF for AF patients with RHD (4.2%), where they also found no significant difference in
stroke risk between AF patients with and without RHD [4]. Possible factors that may contrib-
ute to increased risk of stroke in this young group of vAF patients are co-morbid conditions
including heart failure, genetic predisposition, left atrial enlargement and potentially low time
in therapeutic range for warfarin. A high proportion of AF patients were on anticoagulation
therapy. All AF patients with indication for anticoagulation seeking care at Moi Teaching and
Referral Hospital, a second largest referral hospital in Kenya are routinely referred to anticoa-
gulation clinic, an important feature of AMPATH care introduced by our clinical pharmacists
and very remarkable in the SSA context. However, less than two thirds of these patients had
INR in the therapeutic range. Our results highlight the importance of affordable high-quality
anticoagulation therapy and research into the safety and efficacy of novel oral anticoagulants
in this high-risk group. Data on stroke incidence in vAF cases is not widely reported from
SSA. Forthcoming data from the Global Rheumatic Heart Disease Registry should provide fur-
ther context for our findings [22].
Population-based data and modeling studies demonstrate that AF confers an excess risk of
cardiovascular morbidity and mortality [2,4,23]. However, owing to paucity of data, uncer-
tainty remains on the consequences of vAF in the SSA region. In our analysis, almost one-
third of patients with vAF reported cardiac related hospitalization, while 10% died during 12
months’ follow-up. No significant difference in mortality and hospitalization were detected
between the vAF and nvAF cohort. High rates of adverse events in the vAF patients are likely
due to complications of AF and the fact that these patients tend to present for care at advanced
stages of valvular disease—thereby increasing the probability of severe complications such as
heart failure and stroke. Due to a small sample size and short duration of follow-up, we did not
have sufficient events to assess the determinants of mortality and cardiac related hospitaliza-
tion. Future studies in larger cohorts from this region should be considered to confirm these
findings.
Study limitations
There are several limitations to this study worth highlighting. This study enrolled a conve-
nience sample of patients seeking care at tertiary clinics in western Kenya and it is uncertain
whether the study results can be generalized to other populations. Data on the classification of
AF (paroxysmal, persistent, or chronic) was not available hence, we cannot comment on dif-
ferences in the prognosis of these AF subsets. Onset of AF was by patient self-report which was
not able to be objectively confirmed. Due to a small sample size and short duration of follow-
up, we did not have sufficient number of events to adjust for covariates and we could not cal-
culate adjusted rates for stroke, mortality or cardiac hospitalization.
Conclusion
Despite their relative youth, patients in sub-Saharan Africa with vAF are at increased risk for
adverse cardiovascular events. RHD may be as important as other well-established factors in
predicting adverse cardiovascular outcomes of AF patients in this region. Strategies aimed at
preventing cardiovascular disease risk factors and RHD are needed.
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